Treace(TMCI) - 2025 Q4 - Earnings Call Transcript

Financial Data and Key Metrics Changes - Revenue in Q4 2025 was $62.5 million, a decrease of 9% compared to the prior year period, primarily due to a shift in revenue mix towards lower-priced products [21] - Gross margin was 80.6% in Q4 2025, slightly down from 80.7% in Q4 2024 [21] - Total operating expenses increased to $56.3 million in Q4 2025 from $55.7 million in Q4 2024, reflecting restructuring charges and increased litigation expenses [21] - The net loss for Q4 2025 was $9.4 million, or $0.15 per share, compared to a net loss of $0.5 million, or $0.01 per share, in Q4 2024 [22] - Adjusted EBITDA for Q4 was $6.2 million, down from $11.1 million in Q4 2024, while the full year 2025 Adjusted EBITDA loss was $3.9 million, a 64% improvement over the prior year [22][23] - Cash usage for the full year 2025 was $27.3 million, a 46% reduction compared to $50.5 million in 2024 [23] Business Line Data and Key Metrics Changes - The company has expanded its bunion procedure offerings, now addressing virtually 100% of surgeons' technique preferences for bunion correction [5] - New bunion systems launched in 2025 are expected to significantly increase market penetration and procedure volume growth [10][19] - Over 25% of the surgeon base has incorporated one or more of the new bunion systems into their practice, with Q4 procedure volume growth exceeding mid-single-digit rates [13][19] Market Data and Key Metrics Changes - The overall foot and ankle market was reported to be soft in 2025, with deferrals of elective procedures impacting case volumes [27] - The company anticipates that case volume growth will continue to be offset by product ASP mix-related headwinds in the first half of 2026 [28] - The company expects to capture a larger share of the market with new product launches and improved sales strategies [19][28] Company Strategy and Development Direction - The company is focused on leveraging its existing customer base to drive adoption of new products and expand its serviceable total addressable market (TAM) [10] - Plans for 2026 include launching new products that are expected to enhance market share and profitability [16][19] - The company aims to continue improving its profitability and reducing cash burn, with a target of a 50% reduction in cash usage for 2026 compared to 2025 [23][24] Management's Comments on Operating Environment and Future Outlook - Management noted that broader economic conditions and softer consumer sentiment continue to impact the business environment [7] - The outlook for full year 2026 revenue is projected to be in the range of $200 million to $212 million, representing a decline of 6% to 0% compared to 2025 [8][23] - Management expressed confidence in the strategies in place to restore top-line revenue growth and improve profitability [6][19] Other Important Information - The company has expanded its active surgeon base from nearly 1,300 users in 2020 to over 3,300 users in 2025 [18] - The company has entered the biologics market with new offerings, which are expected to enhance revenue without negatively impacting margins [31] Q&A Session Summary Question: Market conditions and growth outlook - Management acknowledged that the foot and ankle market was soft in 2025, with case deferrals impacting overall surgical volume, but noted an increase in Q4 case volumes [27][28] Question: Impact of biologics on operating margins - Management indicated that the expansion into biologics is expected to provide additional revenue without negatively impacting margins [31] Question: Product development timelines and surgeon feedback - Management confirmed that new products like SuperBite and SpeedXM have been in development for about 18 months and received positive feedback from surgeons [36][38] Question: Balancing sales force focus with new product offerings - Management emphasized that the sales force remains focused on bunion-related products while also addressing adjacent procedures to meet surgeon demand [54][55] Question: Cash flow outlook and cost management - Management detailed initiatives to reduce cash burn and improve profitability, including lower operating expenses and capital expenditures in 2026 [64][66]